Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 20:13:820086.
doi: 10.3389/fphar.2022.820086. eCollection 2022.

Drug Therapies for COPD: A Bibliometric Review From 1980 to 2021

Gao Zhen  1 , Liu Yingying  2 , Dong Jingcheng  1
Affiliations
Review

Drug Therapies for COPD: A Bibliometric Review From 1980 to 2021

Gao Zhen et al. Front Pharmacol. .

Abstract

Objective: To analyze all chronic obstructive pulmonary disease (COPD) drugs-related articles that were indexed in the Web of Science Core Collection (WOSCC) database until August 28, 2021 using bibliometric analysis, in order to provide a reliable reference for the treatment of COPD. Methods: A comprehensive search was conducted to analyze all COPD drugs-related articles using WOSCC database from inception to August 28, 2021. Abstracts and potentially eligible articles, which were retrieved during literature search, were screened by two reviewers. Besides, the CiteSpace (5.8.R1) software was utilized to analyze the overall structure of the network, the network clusters, the links between clusters, the key nodes or pivot points, and the pathways. Results: A total of 2552 COPD-drugs related articles were retrieved. From the perspective of categorization of published articles based on country, the United States is the country with the largest number of published articles and completed clinical trials, highlighting the important role of this country in the treatment of COPD. However, in terms of the proportion of ongoing clinical trials, China has the highest proportion, suggesting that China will play a more pivotal role in the medication of COPD in the future. From the perspective of cooperation among countries, the cooperation among European countries was closer than that among Asian countries. In the recent three decades, the top 20 institutions, with a particular concentration on the treatment of COPD, were from North America and Europe. The co-citation analysis showed that, among 2,552 articles, 53154 citations were recorded, and the co-citation network indicated that 24 clusters could be achieved. Conclusion: The administration of bronchodilators and pulmonary drug delivery systems, as well as consideration of elderly COPD patients remained the hotspots, while triple therapy and comorbidity of COPD, as well as the prevention and treatment of elderly COPD patients had been frontiers in recent years.

Keywords: COPD; bibliometric analysis; elderly; medications; pulmonary drug delivery systems.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
The statistics of COPD drugs-related articles from 1980 to 2021.
FIGURE 2
FIGURE 2
Top 20 countries that published COPD drugs-related studies and the relevant clinical trials from 1980 to 2021.
FIGURE 3
FIGURE 3
Cooperation among countries that published COPD drugs-related studies from 1980 to 2021. Note: (A): countries around the world; (B): European countries; (C): Asian countries; (D): top 8 countries with the strongest citation bursts.
FIGURE 4
FIGURE 4
Annual number of COPD drugs-related studies in each country from 1980 to 2021.
FIGURE 5
FIGURE 5
Cooperation among institutions that published COPD drugs-related studies from 1980 to 2021.
FIGURE 6
FIGURE 6
Top 20 institutions that cooperated in publishing COPD drugs-related studies from 1980 to 2021.
FIGURE 7
FIGURE 7
Research areas of COPD drugs-related studies that were published from 1980 to 2021.
FIGURE 8
FIGURE 8
Cooperation among authors that published COPD drugs-related studies from 1980 to 2021.
FIGURE 9
FIGURE 9
Co-citation analysis of COPD drugs-related studies that were published from 1980 to 2021.
FIGURE 10
FIGURE 10
Keywords analysis of COPD drugs-related studies that were published from 1980 to 2021.
FIGURE 11
FIGURE 11
Keywords co-occurrence analysis of COPD drugs-related studies that were published from 1980 to 2021.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Aaron S. D., Vandemheen K. L., Fergusson D., Maltais F., Bourbeau J., Goldstein R., et al. (2007). Tiotropium in Combination with Placebo, Salmeterol, or Fluticasone-Salmeterol for Treatment of Chronic Obstructive Pulmonary Disease: a Randomized Trial. Ann. Intern. Med. 146 (8), 545–555. Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. 10.7326/0003-4819-146-8-200704170-00152 - DOI - PubMed
    1. Chen C., Dubin R., Kim M. C. (2014). Emerging Trends and New Developments in Re-generative Medicine: A Scientometric Update (2000–2014). Expert Opin. Biol. Ther. 14, 1295–1317. 10.1517/14712598.2014.920813 - DOI - PubMed
    1. Chen C. M. (2006). Citespace II: Detecting and Visualizing Emerging Trends and Transient Patterns in Scientific Literature. J. Am. Soc. Inf. Sci. Technol. 57, 359–377. 10.1002/asi.20317 - DOI
    1. Chronic Obstructive Pulmonary Disease Group of Chinese (2021). Chronic Obstructive Pulmonary Disease Group of Chinese Thoracic Society; Chronic Obstructive Pulmonary Disease Committee of Chinese Association of Chest Physician. [Guidelines for the Diagnosis and Management of Chronic Obstructive Pulmonary Disease (Revised Version 2021)]. Zhonghua Jie He He Hu Xi Za Zhi 44 (3), 170–205. Chinese. - PubMed
    1. Corlateanu A., Covantev S., Mathioudakis A. G., Botnaru V., Siafakas N. (2016). Prevalence and burden of Comorbidities in Chronic Obstructive Pulmonary Disease. Respir. Investig. 54 (6), 387–396. 10.1016/j.resinv.2016.07.001 - DOI - PubMed

LinkOut - more resources